- Gisondi P.
- Zaza G.
- Del Giglio M.
- Rossi M.
- Iacono V.
- Girolomoni G.
|Characteristic||All patients (n = 412)||Patients with positive and presumed-positive results (n = 5)|
|Mean age (SD), y||48.2 (15.9)||48.4|
|Men, No. (%)||196 (48)||2 (40)|
|Women, No. (%)||216 (52)||3 (60)|
|Live in Massachusetts, No. (%)||382 (93)||5 (100)|
|Medications, No. (%)|
|TNFα inhibitor||117 (28.4)||2 (40)|
|IL-17 inhibitor||29 (7)||0|
|IL-23 inhibitor||30 (7.3)||0|
|IL-12/23 inhibitor||54 (13.2)||1 (20)|
|JAK inhibitor||12 (2.9)||0|
|Traditional immunosuppressives No. (%)|
|Methotrexate||48 (11.7)||1 (20)|
|Mycophenolate mofetil||8 (1.9)||0|
|Other immunomodulatory therapies, No. (%)|
|IL-4Rα inhibitor||65 (15.8)||0|
|Apremilast||26 (6.3)||1 (20)|
|Multiple medications (combination of multiple biologics, traditional immunosuppressives, and other immunomodulatory therapies)||18 (4.4)||0|
|COVID-19 outcomes, No. (%)|
|COVID-related hospitalization||1 (0.2)||1 (20)|
|Any cause of death||0||0|
|Degree of contact with others, No. (%)|
|n = 260||n = 5|
|None (patient generally not leaving home)||158 (60.8)||1 (33)|
|Patient with minimal degree of contact at work||31 (11.9)||0|
|Patient with minimal degree of contact at home||31 (11.9)||1 (33)|
|Patient with minimal degree of contact both at work and home||9 (3.5)||0|
|Patient with high degree of contact at work and home||22 (8.5)||1 (33)|
|Household member with high degree of contact at work||9 (3.5)||0|
|COVID-19 symptoms/testing, No. (%)|
|Patients self-reporting symptoms (n = 25)|
|Patients with positive and presumed-positive results (n = 5)|
|Patients with symptoms and positive COVID-19 PCR test result||2 (8)||2 (40)|
|Patients with symptoms and negative COVID-19 PCR test result||9 (36)||1 (20)|
|Patients with symptoms who were not tested for COVID-19||14 (56)||2 (40)|
Information on the outbreak of coronavirus disease 2019 (COVID-19).
- Should biologics for psoriasis be interrupted in the era of COVID-19?.J Am Acad Dermatol. 2020; 82: 1217-1218
- Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment.J Am Acad Dermatol. 2020; 83: 285-287
- COVID-19 infection: the perspectives on immune responses.Cell Death Differ. 2020; 27: 1451-1454
- Information on the outbreak of coronavirus disease 2019 (COVID-19).https://www.mass.gov/resource/information-on-the-outbreak-of-coronavirus-disease-2019-covid-19Date: 2020Date accessed: May 8, 2020
- COVID-19: risk for cytokine targeting in chronic inflammatory diseases?.Nat Rev Immunol. 2020; 20: 271-272
Funding sources: None.
Conflicts of interest: Dr Rosales Santillan has received fellowship funding from AbbVie and Janssen that went directly to her institution. Dr Her's spouse works for AbbVie. Dr Kimball is a consultant and investigator for AbbVie, Bristol Meyers Squibb, Janssen, Eli Lilly, Novartis, Pfizer, and UCB; a consultant for Kymera and AmirallInvestigator ChemoCentryx; receives fellowship funding from Janssen and AbbVie ; served on the board of directors and served as president of the International Psoriasis Council; and served on the board of directors of the HS Foundation. Dr Porter is a consultant and investigator for UCB, Pfizer, Eli Lilly, and Novartis and an investigator for AbbVie, Janssen, and Bristol Meyers Squibb. Dr Holcomb and Authors Morss-Walton, Salian, and Giannotti have no conflicts of interest to declare.
Reprints not available from the authors.